December 11, 2023 PAI Top-10 Product Launch

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 – Roche (SIX: RO, ROG;... Read more

December 9, 2023 PAI Top-10 Product Launch

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of... Read more

December 8, 2023 PAI Top-10

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2 Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2 These data will be presented as an oral presentation at the 2023 San Antonio... Read more

December 8, 2023 Uncategorized

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1 The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium... Read more

December 7, 2023 Microscopy Molecular Spectroscopy Product Launch

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers Read more

December 6, 2023 Lab Top-10

Danaher Completes Acquisition of Abcam

WASHINGTON, Dec. 6, 2023 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the “Scheme”) and the Scheme became effective... Read more